Skip to main content
. 2023 Oct 3;7(10):e957. doi: 10.1097/HS9.0000000000000957

Figure 3.

Figure 3.

CH and CAR T-therapy toxicity. (A, B) Histogram plots showing prevalence of CRS/ICANS (onset: filled, no onset: hatched) according to the absence (n = 48, green) or presence (n = 62, orange) of clonal hematopoiesis across the total cohort (n = 110, gray). (C) Histogram plots illustrating prevalence of cytopenias at day 100 after CAR T-cell therapy as defined by leukopenia (total WBC count <3000/µL) and/or thrombocytopenia (platelet count <100,000/µL) and/or anemia (hemoglobin <10 g/dL) in patients with available information (n = 74) according to the presence (n = 46) or absence (n = 28) of CH with a VAF cutoff 1%. CAR = chimeric antigen receptor; CH = clonal hematopoiesis; CRS = cytokine release syndrome; ÍCANS = immune effector-cell-associated neurotoxicity syndrome; VAF = variant allele frequency.